Scientific publications

Gangliosides and parkinsonism

Herrero MT, Kastner A, Perez-Otaño I, Hirsch EC, Luquin MR, Javoy-Agid F, Del Río J, Obeso JA, Agid Y.
INSERM U289, Hôpital de la Salpêtrière, Paris, France.

Magazine: Neurology

Date: Sep 30, 1993

Neurology [SP]

The protective effect of GM1 ganglioside against nerve cell death induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was analyzed in monkey mesencephalon. Administration of GM1 before and during MPTP treatment improved motor performances compared with MPTP-treated animals that received saline rather than GM1.

Postmortem analysis revealed that GM1 did not protect dopaminergic cell bodies from MPTP intoxication but resulted in an increased immunoreactivity of tyrosine hydroxylase in the perikarya and processes of the surviving neurons.

These data suggest that GM1 may be potentially used as a palliative rather than a curative therapy in Parkinson's disease.

CITATION  Neurology. 1993 Oct;43(10):2132-4

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra